Biodesix reports 17% core revenue growth for Q1
BOULDER — Biodesix Inc. (Nasdaq: BDSX), a diagnostics company that specializes in lung disease, reported a 17% year-over-year increase in core revenue related to its lung diagnostics for the first quarter of 2022, to $4.6 million from $3.9 million.
Overall revenue for the first quarter declined 77% year-over-year, mostly due to a 96% decrease in revenue from COVID-19 diagnostics “in line with expectations as the pandemic recedes and COVID testing trends continue to move to at-home testing,” according to a news release.
Biodesix posted a net loss of $15.6 million for the quarter, up from $6.9 million in the first quarter of 2021. It has $16.4 million in cash and equivalents on hand.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
The company expects to generate between $37.5 million and $39.5 million in revenue for the 2022 fiscal year.
BOULDER — Biodesix Inc. (Nasdaq: BDSX), a diagnostics company that specializes in lung disease, reported a 17% year-over-year increase in core revenue related to its lung diagnostics for the first quarter of 2022, to $4.6 million from $3.9 million.
Overall revenue for the first quarter declined 77% year-over-year, mostly due to a 96% decrease in revenue from COVID-19 diagnostics “in line with expectations as the pandemic recedes and COVID testing trends continue to move to at-home testing,” according to a news release.
Biodesix posted a net loss of $15.6 million for the quarter, up from $6.9 million in the first quarter of…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
